Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Algae, particularly certain species such as Spirulina, Chlorella, and various seaweeds (e.g., Ulva, Laminaria), have been investigated for their potential benefits in supporting or treating Inflammatory Bowel Disorders (IBD), including Crohn’s disease and ulcerative colitis. The rationale for their use is primarily based on their rich content of bioactive compounds, such as polysaccharides (e.g., fucoidan, alginate), polyphenols, omega-3 fatty acids, and antioxidants, which are thought to modulate immune responses and inflammation.

Preclinical studies (mainly in animal models) have demonstrated that certain algae extracts can reduce inflammation, modulate gut microbiota, and improve markers of intestinal barrier function. For example, fucoidan from brown seaweed has shown anti-inflammatory effects in colitis models, possibly by downregulating pro-inflammatory cytokines and oxidative stress. However, clinical evidence in humans remains limited. Small pilot studies suggest some benefit in symptom relief and inflammatory markers, but large, well-controlled human trials are lacking.

In conclusion, while there is promising scientific rationale and some preclinical evidence for using algae and their extracts in IBD, the current level of evidence is moderate at best (rated 2/5). More rigorous human studies are needed before algae can be recommended as a standard adjunct or treatment for IBD.

More about Algae
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Algae

Products containing Algae

Douglas Laboratories THYROMEND™